ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.

As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.

Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.

We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.